A5052553989- Cardiac Arrest and Resuscitation
- Diabetes Treatment and Management
- COVID-19 and healthcare impacts
- Mechanical Circulatory Support Devices
- Parathyroid Disorders and Treatments
- Hemoglobinopathies and Related Disorders
- Potassium and Related Disorders
- Cardiac pacing and defibrillation studies
- Heart Failure Treatment and Management
- Acute Myocardial Infarction Research
Radboud University Nijmegen
2024
Erasmus University Rotterdam
2024
Erasmus MC
2023
Amphia Ziekenhuis
2022
Jessa Hospital
2021
The current study aimed to evaluate changes in treatment delay and outcome for ST-segment elevation myocardial infarction (STEMI) the Netherlands during first coronavirus disease 2019 (COVID-19) outbreak, thereby comparing regions with a high low COVID-19 hospitalisation rate.Clinical characteristics, STEMI timing variables, 30-day all-cause mortality cardiovascular complications of all consecutive patients admitted from 1 January 30 June 2020 six hospitals performing volume percutaneous...
Abstract Background Sodium glucose co-transporter 2 inhibitors (SGLT2-i) are one of the four pillars guideline-directed medical therapy in heart failure with reduced ejection fraction and preserved according to current ESC AHA/ACC guidelines 1,2. As a result, there has been significant increase their use worldwide. Although SGLT2 known hemoglobin hematocrit levels, is lack data on burden erythrocytosis or polycythemia pivotal trials 3,4. Purpose In this retrospective cohort study, we...